Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-1.69
EPS est.
$-1.26
EPS surprise
-34.13%
1-day move
-1.95%
Vera Therapeutics reported a larger-than-expected loss per share, which contributed to a decline in the stock price by 1.95%. Investors may be concerned about the company's financial performance given the EPS miss. The lack of revenue and guidance updates adds to the uncertainty surrounding the company's future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.69 | $-1.37 | -34.13% |
| Revenue | $0M | $0M | N/A |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Vera Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious diseases. With a market cap of $3 billion, it operates in the health care sector, which is seeing increased attention due to advancements in medical treatments and the ongoing demand for innovative solutions.
Last quarter
In Q4 2025, Vera Therapeutics reported an EPS of $-4.66, significantly missing expectations. The stock reacted positively, gaining 1.61% the following day despite the disappointing results.
EPS beat streak
1Q
EPS beat rate
13%
Avg EPS surprise
-45.42%
Avg 1-day reaction
-1.92%
Analysts are expecting another challenging quarter for Vera, with a consensus EPS of $-1.37. Investors will be closely monitoring any signs of progress in product development.
Bull case
If Vera can demonstrate advancements in its drug pipeline or secure partnerships, it could lead to a positive shift in investor sentiment and stock performance.
Bear case
Continued losses and lack of revenue could raise concerns about the company's viability and lead to further stock declines.
Key metrics to watch
EPS
$-1.37Earnings per share is a critical measure of profitability and will indicate how well the company is managing its expenses.
Revenue
$0MAlthough no revenue is expected this quarter, any updates on product development or partnerships could signal future revenue potential.
The print will turn on these.
Q1
Will Vera provide any updates on its drug pipeline or potential partnerships?
Investors are keen to understand the company's future revenue potential, especially given the lack of expected revenue this quarter.
Q2
How does management plan to address the significant EPS losses reported in previous quarters?
Management's strategy for reducing losses will be critical for investor confidence and could influence stock performance.
—
Est. EPS
$1.57
Est. Rev
$464M
Impl. Move
±7.2%
Why consensus could be wrong
The Street may underestimate the potential for Vera's drug pipeline to yield results sooner than anticipated, particularly in light of recent industry trends.
Supporting evidence
The options market indicates a high expected move, suggesting that traders foresee significant developments.
Insider selling may reflect a strategic repositioning rather than a lack of confidence in the company's future.
Key risk
If any unexpected positive news about the drug pipeline emerges, it could significantly alter the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for future growth against the backdrop of ongoing losses, making this quarter's results particularly pivotal.
Bull confirmed if
A narrower EPS loss than the consensus of $-1.37 could signal improved cost management.
Bear confirmed if
An EPS loss greater than $-1.37 would reinforce concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±10.98%
Historical Avg
±3.3%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±9.8% while VERA has averaged ±3.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
45.0%
Smart-money positioning from the most recent 13F filings.
Institutional
118.09%
of float
Insider
0.95%
of float
Holders
311
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,747,760 sh · $173.9M
7.98%
13.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Vera beats EPS expectations, history suggests the stock could rise by an average of 3.1%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A significant miss could lead to a decline in stock price, with historical patterns indicating an average drop of 2.18%.
The lines on the call that would change the story.
Avoro Capital Advisors LLC
5,723,888 sh · $173.1M
7.94%
-2.8%
State Street Corporation
4,148,786 sh · $125.5M
5.76%
23.3%
Price (T.Rowe) Associates Inc
4,012,936 sh · $121.4M
5.57%
-12.3%
Deep Track Capital, Lp
4,000,000 sh · $121.0M
5.55%
-2.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.